139 results about "Silicosis" patented technology

A method of reducing silicosis caused by inhalation of silica-containing proppant, such as silica sand and resin-coated silica sand, and apparatus therefor. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.

A method of reducing silicosis caused by inhalation of silica-containing proppant, such as silica sand and resin-coated silica sand, and apparatus therefor.

The invention relates to therapeutic antisense oligonucleotides directed against genes coding for phosphodiesterase (PDEs) and the use of these in combination. These antisense oligonucleotides may be used as analytical tools and / or as therapeutic agents in the treatment of disease associated with reduced cellular cAMP in a patient, such as inflammatory diseases of the respiratory tract including, for example, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, bronchitis, chronic bronchitis, silicosis, pulmonary fibrosis, lung allograft rejection, allergic rhinitis and chronic sinusitis as well as other conditions in which an increase in cyclic AMP or a decrease in PDE levels is beneficial.

A method of reducing silicosis caused by inhalation of silica-containing proppant, such as silica sand and resin-coated silica sand, and apparatus therefor. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.

The invention discloses bletilla polysaccharide, a preparation method and novel application thereof. The bletilla polysaccharide is prepared by the following method: firstly, coarse bletilla powder is taken as a raw material, and is extracted by alcohol; secondly, herb residue is extracted by water; thirdly, resin is used for removing proteins of a concentrated solution; and fourthly, after an eluent is condensed, the bletilla polysaccharide is precipitated by the ethanol. The content of the bletilla polysaccharide prepared by the method is high, reaches 70 to 74 percent, and is improved by 14 to 20 percent compared with the prior technical method, and the bletilla polysaccharide has good protein removal effect. The preparation method can also utilize the herb residue produced in the process of production of bletilla particle medicines as the raw material, so as to save the production cost. The invention also provides the novel application of the bletilla polysaccharide to preparation of medicines for treating gastric ulcer and medicines for treating silicosis and a commonly used medical preparation formulation.

The invention relates to an environmentally friendly bio-soluble refractory fibre and a production process thereof; the fibre comprises the following components according to the parts by weight: 58-76 parts of silicon dioxide, 24-38 parts of calcium oxide and 4-20 parts of magnesium oxide. The production process comprises the following steps: A. resistance furnace melting: silicon dioxide, calcium oxide and magnesium oxide are placed in a resistance furnace to melt to liquid at a raw material melting temperature of 1500-1800 DEG C; B. thread throwing: throwing the molten liquid to threads with high speed whirling rollers at a fiber forming temperature of 1400-1500 DEG C. The production process has the advantage that the process has little harm to human body and can effectively prevent occupational diseases such as silicosis and the like or canceration which is directly caused.

The invention discloses a silicosis treatment aerosol containing a human mesenchymal stem cell exosome extract and a preparation method thereof, wherein the main component of the aerosol is the high-concentration mesenchymal stem cell exosome extract. The mesenchymal stem cells can secrete various cell factors in the culture process, and the cell factors can penetrate into the basal layer of an inner membrane, promote tissue differentiation of the inner membrane, angiogenesis and growth of granulation tissues, promote regeneration and repair of damaged skin tissue structures, reduce generation of scar connective tissues and reduce bacterial infection and inflammatory reaction of wound surface tissues. According to the aerosol and the preparation method thereof, a method of continuous starvation of the mesenchymal stem cells is adopted, a high-concentration human mesenchymal extract can be obtained in a short period of time, and a big amount of stem cell exosomes can be separated from the mesenchymal extract by an exosome extractor. The aerosol containing the high-concentration mesenchymal stem cell exosome extract disclosed by the invention is suitable for the restoration and treatment of silicosis.

The invention provides compounds of Formula (I), stereoisomers thereof, or pharmaceutically acceptable salts of said compounds or stereoisomers, wherein R1, R2, m, p, q, R7 and R8 are as defined below, as well as compositions comprising the same, processes for making the same, and methods of using the same to treat a variety of diseases, including, those requiring interaction with metalloproteases, and more specifically with macrophage metalloelastase (MMP-12), and for the prevention and treatment of respiratory pathologies such as chronic obstructive bronchopneumopathy (COPD), emphysema, chronic bronchitis, chronic pulmonary inflammation, asthma, cystic fibrosis, acute respiratory distress syndrome (ARDS), respiratory allergies including allergic rhinitis, and also diseases associated with the production of TNFα including severe fibrotic pulmonary disease, pulmonary sarcoidosis and silicosis. The compounds of the present invention also show inhibitory activity on metalloprotease-13 (MMP-13), making them useful for the treatment of pathologies involving this enzyme, such as cancer, osteoporosis, osteoarthritis, arthritis, rheumatoid arthritis, atherosclerosis, multiple sclerosis and cardiac insufficiency.

The invention discloses a fireworks safety firing cable and a manufacturing method thereof. The fireworks safety firing cable comprises an ignition-composition core and cotton yarn attached with firing cable compositions; and the manufacturing method is mainly characterized by comprising the following steps: adding an appropriate amount of organic solvents into the prior firing cable compositions, and evenly stirring to enable the compositions to be in a thick fluid flurry state; and evenly attaching the fluid slurry onto priming cotton yarn as a firing cable composition core by improving the structure of a priming machine. The invention has the advantages that a plurality of process flows with higher hazards are reduced in the processing process of firing cable compositions, the defect that composition powder is interspersed in production places is avoided in the cotton yarn wrapping process, and the production security is improved qualitatively; the quality of the product is improved, and the phenomena of composition interruption, shortage and leakage are prevented from generating; no dust pollution is generated in production and application, and production personnel are avoided from being injured by occupational diseases, such as silicosis, and the like.

The invention discloses a traditional Chinese medicine for silicosis treating. The traditional Chinese medicine comprises, by weight, 20-30 parts of lilies, 20-30 parts of tendril-leaved fritillary bulbs, 10-20 parts of radix paeoniae alba, 10-20 parts of sculellaria barbata, 10-20 parts of hedyotis diffusa, 10-15 parts of scutellaria baicalensis, 10-20 parts of gardenia, 10-20 parts of fructus forsythiae, 20-30 parts of cordate houttuynia, 10-20 parts of safflower carthamus, 5-10 parts of peach seeds, 10-20 parts of angelica sinensis, 20-30 parts of folium eriobotryae, 10-20 parts of almond, 10-15 parts of flos farfarae, 10-15 parts of radix stemonae, 10-20 parts of aster, 15-25 parts of platycodon grandiflorum, 10-20 parts of radix ophiopogonis, 20-30 parts of the roots of kudzu vine, 30-40 parts of astragalus membranaceus, 10-20 parts of mair conditioning unita, 10-20 parts of codonopsis pilosula, 5-10 parts of sappanwood, 10-15 parts of poria cocos, 10-15 parts of ligusticum wallichii, 10-15 parts of panax notoginseng and 5-10 parts of liquorice. The traditional Chinese medicine for silicosis treating can nourish lungs and kidneys and achieve internal and external therapy.

The invention provides a stem cell derived exosome preparation for preventing and treating lung jury. Lung injury includes acute lung injury, radiation lung injury, pulmonary fibrosis, silicosis and the like. The preparation is prepared from stem cell derived exosomes, and after a trachea cannula or intravenous injection reaches injured lungs, recovery of injured tissue structure and function is promoted; the preparation is an acellular preparation, so that the risk of cell mutation is lowered; the stem cell derived exosomes repair and maintain the function in lung tissue; treatment effect oflung injury and fibrosis is enhanced.

The invention provides an application of a traditional Chinese medicine composition in the preparation of medicines for treating silicosis. The medicine composition comprises 12 types of traditional Chinese herbs of ginseng, radix ophiopogonis, dogwood and the like. Clinical tests prove that the medicine composition used for treating the silicosis can obviously ameliorate clinical symptoms and the lung function and has favorable curative effect.

Methods are disclosed for treating, preventing or reducing the risk of developing occupational lung diseases, such as pneumoconiosis. In several embodiments, the methods include administering a therapeutically effective amount of the suppressive ODN to a subject having or at risk of developing a pneumoconiosis, thereby treating or inhibiting the pneumoconiosis. In several examples, thee subject can have or be at risk of developing silicosis, asbestosis or berryliosis. The method can include selecting a subject exposed to, or at risk of exposure to, inorganic particles, including, but not limited to silica, asbestos, berrylium, coal dust, or bauxite.

The invention discloses a medicine for treating silicosis. The medicine comprises the following raw traditional Chinese medicines in parts by weight: 30-50 parts of houttuynia cordata, 20-30 parts of ardisia japonica, 20-30 parts of ligusticum wallichii, 20-30 parts of salvia miltiorrhiza, 10-20 parts of fritillaria thunbergii, 15-30 parts of mulberry bark, 10-30 parts of codonopsis pilosula, 20-50 parts of astragalus mongholicus, 20-30 parts of rhizoma alismatis, 10-20 parts of liquorice, 10-20 parts of angelica sinensis, 15-30 parts of rehmannia glutinosa, 10-20 parts of semen persicae, 15-20 parts of achyranthes bidentata, 10-20 parts of schisandra chinesis, 10-20 parts of radix paeoniae rubra, 10-15 parts of radix sileris, 15-30 parts of trichosanthes peel, 15-20 parts of rhizoma sparganii, 15-20 parts of rhizoma zedoariae, 10-20 parts of almond, 10-15 parts of cassia twig, 10-20 parts of loofah sponge, 12-20 parts of adenophora stricta, 10-30 parts of lily and 15-20 parts of radix paeoniae alba. The medicine has the advantages that the medicine has an obvious treatment effect on the silicosis, takes the effect rapidly, is low in cost, and has no side effects.

The invention discloses an establishment device and evaluation method for a silicosis animal model. The device is divided into three parts communicating from top to bottom, the upper part is a silicious dust aerosol generation device, the middle part is an animal dust contamination cabinet, and the lower part is a waste gas treatment device; the silicious dust aerosol generation device is used forsilicious dust generation and comprises a tank, a silicious dust stirring device arranged in the tank and a leaking plate arranged at the bottom of the tank; an upper layer and a lower layer are arranged in the dust contamination cabinet, the upper layer is a uniform silicious dust aerosol mixing device, and the lower layer is a rat fixing and dust suction device; an opening is formed in the waste gas treatment device and connected with a filtering dust removal bag; and each connection part is subjected to seal treatment. The invention further provides the method for establishing and evaluating the silicosis animal model by using the device. The establishment device and evaluation method can conveniently and simply establish the effective silicosis animal model, provide a good work basisfor research on the silicosis pathogenesis and treatment, and also provide an objective, direct and reliable standard for the silicosis animal model.

The invention discloses application of obaculactone in preparation of drugs for treating pulmonary fibrosis, chronic pneumonia and chronic bronchitis and a chronic obstructive pulmonary disease or asthma, and further discloses the related drugs. Obaculactone can effectively and dose-dependently improve the bleomycin-induced mouse pulmonary fibrosis damage and the inflammation symptoms generated in the pathogenic process of the mouse pulmonary fibrosis damage through oral administration. Detection on collagen synthesis shows that obaculactone can dose-dependently regulate down generation of alpha-SMA and collagen, and the effect is based on inhibition of obaculactone on a TGF-beta signal channel in the mouse pulmonary fibrosis tissue. The results show that obaculactone can be applied to multiple inflammation-mediated chronic lung diseases including the pulmonary fibrosis, the chronic pneumonia, silicosis, the chronic bronchitis, the chronic obstructive pulmonary disease and the asthma.

The invention relates to therapeutic antisense oligonucleotides directed against genes coding for phosphodiesterase (PDEs) and the use of these in combination. These antisense oligonucleotides may be used as analytical tools and / or as therapeutic agents in the treatment of disease associated with reduced cellular cAMP in a patient, such as inflammatory diseases of the respiratory tract including, for example, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, bronchitis, chronic bronchitis, silicosis, pulmonary fibrosis, lung allograft rejection, allergic rhinitis and chronic sinusitis as well as other conditions in which an increase in cyclic AMP or a decrease in PDE levels is beneficial.

The present invention discloses a new use of ginsenoside M1 for treating or preventing silicosis.

A composite medicine in the form of injection or orally taken solid or liquid for treating asthmatic chronic bronchitis, acute bronchal asthma, lung infection, pneumonia, pneumonectasis, cardiogenic asthma, pulmonary tuberculosis, silicosis, etc is prepared from indianmulberry root or its extract and picrorhiza rhizome or its extract. Its preparing process is also disclosed.

The invention relates to a method for separating and preparing tetrandrine and hanfangchin through ion exchange and column chromatography on silica gel. Fourstamen stephania root is dried root of a menispermaceae stephania plant stephania tetrandra, an effective ingredient of the fourstamen stephania root is sinomenine, main effective ingredients of sinomenine are tetrandrine and hanfangchin, and the sinomenine has anti-myocardial ischemia, anti-arrhythmia, blood pressure lowering, anti-inflammatory, anti-silicosis, anti-cancer and analgesic effects. When in drug use, the purity requirement of the tetrandrine and hanfangchin reaches more than 99%, and extraction and purification are important reasons limiting the drug use of the tetrandrine and hanfangchin. At present, a technology for extracting and purifying the tetrandrine and hanfangchin applies massive toxic and expensive chloroform and strong base, and the chloroform has great toxic effect on human and the environment and is also strong corrosive on equipment for enlarged production; besides, sample purity is not high, and a technological process is complex. At the current situation, the invention develops a method for obtaining high-purity tetrandrine and hanfangchin through rapid separation and purification by applying ion exchange resin and a C18 bonded silica gel column chromatography and also discloses a method for recrystallizing and purifying the tetrandrine and hanfangchin by utilizing ethyl alcohol. The method provided by the invention has the advantages that a preparation technology does not apply any toxic reagent, column chromatography filler can be recycled, and ethyl alcohol can be recycled.

The invention provides compounds of Formula (I), stereoisomers thereof, or pharmaceutically acceptable salts of said compounds or stereoisomers wherein R1 and R2 are as defined herein as well as compositions comprising the same, processes for making the same, and methods of using the same to treat a variety of diseases, including, those requiring interaction with metalloproteases, and more specifically with macrophage metalloelastase (MMP-12), and for the prevention and treatment of respiratory pathologies such as chronic obstructive bronchopneumopathy (COPD), emphysema, chronic bronchitis, chronic pulmonary inflammation, asthma, cystic fibrosis, acute respiratory distress syndrome (ARDS), respiratory allergies including allergic rhinitis, and also diseases associated with the production of TNFα including severe fibrotic pulmonary disease, pulmonary sarcoidosis and silicosis. The compounds of the present invention also show inhibitory activity on metalloprotease-13 (MMP-13), making them useful for the treatment of pathologies involving this enzyme, such as cancer, osteoporosis, osteoarthritis, arthritis, rheumatoid arthritis, atherosclerosis, multiple sclerosis and cardiac insufficiency.

A method of reducing silicosis caused by inhalation of silica-containing proppant, such as silica sand and resin-coated silica sand, and apparatus therefor. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.

The invention provides a health drink and a preparation method thereof. The method comprises the following steps: boiling soaked red dates, tuckahoe, medlar and lichees, filter-pressing the ingredients to obtain extracts, respectively adding honey water solution and sucrose solution, heating the solutions to the temperature of 80-85 DEG C and adding sodium benzoate, continuously increasing the temperature to 70-75 DEG C after holding deposition and filtration, sequentially adding protein hydrolysate, iron lactate, zinc gluconate, calcium lactate, vitamin C and citric acid, stirring the substances at the temperature of 80-85 DEG C for 10-15min and then carrying out filling and sealing to product finished products. The health drink of the invention is specially prepared for silicosis, which can effectively prevent silicosis and improve silicosis symptoms if the workers exposed to dust often take the drink.

The invention relates to a traditional Chinese medicine for treating silicosis, and belongs to the field of traditional Chinese medicines for treating respiratory diseases. The traditional Chinese medicine aims to achieve good effect and quick response. The traditional Chinese medicine is prepared from greenish lily bulb, notoginseng root, rehmanniae praeparatum, common bletilla pseudobulb, spreading hedyotis herb, glossy ganoderma,, Indian iphigenia bulb, Chinese angelica and the like, has the effects of strengthening body resistance and archaeus, supplementing qi and nourishing blood, resolving hard lumps to dissipate stagnation, promoting blood circulation by removing blood stasis and moistening lung to relieve cough, and has the advantages of obvious effect, definite curative effect and quick response.

The invention relates to a decoction for treating silicosis and a preparation method thereof. The decoction is prepared from raw materials of low-cost traditional Chinese medicinal herbs, which mainly include red-rooted salvia root, red paeony root, Szechuan lovage rhizome, pinellia tuber, plantain herb, platycodon root, hairy asiabell root, manyflower solomonseal rhizome, root of straight ladybell, liquorice and the like, and the decoction is simple in preparation method and is obtained through decocting based on reasonable compatibility according to the basic principle of strengthening the body resistance to eliminate pathogenic factors. According to the invention, because the traditional Chinese medicinal herbs are adopted, the decoction has low cost and can be popularized and used in a large range; due to adoption of the pure natural Chinese medicinal herbs, not only is the curative effect enhanced based on the synergism of all medicinal herbs, but also the side effects of the medicinal herbs are reduced, and the decoction is easy to accept by patients; and the decoction can be used to alleviate onset pains of the patients, is suitable for being taken by patients of all age groups suffering from the silicosis of various stages, and has a short treat course and rapid response.

A method of reducing silicosis caused by inhalation of silica-containing proppant, such as silica sand and resin-coated silica sand, and apparatus therefor. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.

The invention relates to a preparation method of silicosis mouse models. The preparation method of the silicosis mouse models is characterized in that after experiment preparation, isoflurane in an anesthesia machine is adopted to anesthetize mice in a model group, 3 seconds after rapid-shallow breaths of the mice become deep and slow, each mouse is taken out and placed at the center of a palm, the tip of a thumb presses against the underjaw of each mouse, a micropipette is adopted to instill a SiO2 micro-sized particle suspension through the nose of each mouse, the SiO2 micro-sized particle suspension is instilled into the nose wings to be absorbed, closed-chest massage is conducted for 2-3 minutes, then the mice are placed into cages, and after an experiment is finished, the mice are sent back to a normal-temperature animal feed room; only normal saline of the same volume is used for conducting nasal inhalation on mice in a contrast group; weight indexes of the mice are obtained before and after the experiment, the mice are killed at the first week, the second week, the fourth week, the eighth week and the sixteenth week respectively, lung tissue is taken to be pathologically andbiochemically compared and identified, and a model preparation effect is evaluated. According to the preparation method of the silicosis mouse models, a model production technology is stable and efficient; the method can be repeated many times and is noninvasive, environmentally friendly and humanistic, and labor and time are saved.

The invention provides a talc ore beneficiation method. The talc ore beneficiation method is characterized in that by utilizing difference of friction coefficients between talc ores and a steel plate and between gangues and the steel plate and different hydrophilic properties of the talc ores and the gangues, and by means of combination of water flow and mechanical rotation, the purpose that the talc ores are effectively separated from the gangues is achieved. The invention further discloses a talc ore beneficiation device which is provided with water flow and based on the talc ore beneficiation method. The talc ore beneficiation device comprises a large horizontal steel rotary drum, the large rotary drum support seat, a separating scrapping plate, a feed port, a talc ore discharge port, a gangue discharge port and more than one power unit, wherein the power units are used for driving the large rotary drum and the separating scrapping plate to rotate. The talc ore beneficiation method and the talc ore beneficiation device have the advantages that beneficiation efficiency and separation precision of the talc ores are improved, dust is reduced, the risk that operating staff suffer from silicosis is lowered, noise is lowered, the working environment of the operating staff is improved, mechanical abrasion between the separating scrapping plate and the large rotary drum is reduced, and the service life of the device is prolonged.

The invention discloses a Chinese medicament for treating silicosis, which consists of the following raw material medicaments in part by weight: 3 to 7 parts of danshen root, 3 to 7 parts of cherokee rose fruit, 3 to 7 parts of common selfheal fruit-spike, 3 to 7 parts of platycodon root, 3 to 7 parts of hawthorn fruit, 3 to 7 parts of common bletilla pseudobulb, 3 to 7 parts of sessile stemona root, 3 to 7 parts of coastal glehnia root, 3 to 7 parts of vine of multiflower knotweed, 2 to 6 parts of combined spicebush root, 2 to 6 parts of whiteflower hogfennel root, 2 to 6 parts of hairyvein agrimonia herb and bud, 2 to 6 parts of liquoric root, 2 to 6 parts of earthworm, 2 to 6 parts of grassleaf sweelflag rhizome, 2 to 6 parts of chicken's gizzard-membrane, 2 to 6 parts of manchurian wildginger and 2 to 6 parts of common scouring rush herb. The Chinese medicament for treating the silicosis has the effects of activating blood and dissolving stasis, resolving hard lump, dispelling wind damp, disinhibiting water and dispersing swelling, clearing heat and detoxicating, moistening the lung and suppressing cough, lowing sputum consistency and promoting sputum excretion, and has the effects of improving cardio-pulmonary functions. The Chinese medicament has pure Chinese medicinal components and has the characteristics of reasonable formula, simple and convenient administration, obvious treatment effect and the like. 50 clinical application cases prove that total effective rate of the medicament reaches 96 percent.

The invention relates to an establishment method of a silicosis pulmonary fibrosis animal model and a special intubation device. The establishment method comprises the following steps: (1) narcotizingand fixing a rat, and exposing the glottis of the rat; (2) under the irradiation of a cold light source, inserting an intubation assembly into a tracheae; (3) observing the change situation of liquidlevel of a detection assembly, and judging that the intubation assembly has been inserted into the tracheae if the liquid level fluctuates; and (4) after the intubation assembly has been inserted into the tracheae, injecting SO2 turbid liquid into the rat. The provided method and intubation device has the advantages that by setting a detection assembly, people can judge whether the intubation iscorrect or not, the death rate of the rat is reduced therefore, and the success rate of model construction is increased.